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Abstract 
Here after performing docking and molecular dynamics of various small 
molecules derived as a secondary metabolite from fungi, we propose Flaviolin to 
act as potent inhibitor of 3-chymotrypsin (3C) like protease (3CLpro) of noval 
corona virus SARS-CoV2 responsible for pandemic condition caused by 
coronavirus disease 2019 (COVID-19). 
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 The onset of 2020 witnessed the world brought to a virtual standstill with the outbreak of a novel 
severe acute respiratory syndrome virus (SARS-CoV-2). The coronavirus disease 2019 (COVID 
2019) pandemic of the 21st century began as an outbreak in China in 2019 and soon, it overwhelmed 
the world, ultimately leading the World Health Organization to declare it as a global pandemic in 
March 2020. As on 28th March 2020, more than 500,000 confirmed cases in 202 countries were 
infected with the deadly SARS-CoV-2 virus with more than 23,000 deaths globally. With no apparent 
approved or clinically tested anti-viral drug for SARS-CoV, the race to find an efficient therapeutic 
has become the primary motive for the affected nations(de Wit, van Doremalen, Falzarano, & 
Munster, 2016; Jin, Du, Xu, Deng, Liu, Zhao, Zhang, Li, Zhang, Peng, et al., 2020; Wu et al., 2020; 
Zhou et al., 2020).  
 The genome of coronaviruses contains 25 to 32 kb, which encodes two large and overlapping 
polyproteins, pp1a and pp1ab, which are vital for the replication, transcription and therefore the 
proliferation of the virus within the host. The functional polypeptide is acted upon by virally encoded 
3-chymotrypsin (3C) like protease (3CLpro), known as main protease. Though, 3CLpro is a dimer, 
which provides the substrate binding cleft, the protease carries out its proteolytic activity by the 
nucleophilic attack guided by cysteine thiol in its Cys-His dyad. Owing to the vitality of 3CLpro in 
realizing the viral life cycle and the absence of its human analogue, 3CLpro is a prime target for the 
design of anti-SARS-CoV-2 drug design(Jin, Du, Xu, Deng, Liu, Zhao, Zhang, Li, Zhang, Peng, et 
al., 2020; Jin, Du, Xu, Deng, Liu, Zhao, Zhang, Li, Zhang, & Peng, 2020; F. Wang, Chen, Tan, Yang, 
& Yang, 2016). 
 In the present study, hundred secondary metabolites of fungi were screened virtually to assess its 
molecular docking with 3CLpro in silico. The natural chemical compounds/fungal metabolites were 
screened based on their in-silico binding energy, formation of hydrogen bonds to 3CLpro.  Flaviolin 
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was found to be the most ideal compound to bind with 3CLpro, which was corroborated with 
molecular dynamics study of the flabiolin-3CLpro complex for 1000 ps. The stability of the complex 
could possibly pave a path for identifying/realizing the anti-3CLpro mode of action of Flaviolin. The 
protein 3CLpro was retrieved from Protein databank (PDB), ID 7LU6. The protein was co-crystallized 
with its cognate ligand, N3 (PubChem CID: 6323191). The co-ordinates of N3 binding site on 3CLpro 
were determined using UCSF Chimera (version 1.14).  The protein structure was prepared for 
docking by addition of H-bonds and removal of all the co-crystallized residues (Figure 1). The energy 
minimization step was performed out using DockPrep tool (Krivov, Shapovalov, & Dunbrack, 2009). 
AM1-BCC method, known for its promptness in assigning charges to the molecules, was employed 
using ANTECHAMBER algorithm. while assigning the charges (J. Wang, Wang, Kollman, & Case, 
2001). Energy minimization was performed using 500 steepest descent steps with 0.02 A° step size 
with an update interval of 10.  All the steps mentioned were performed in Chimera.   
 The fungal secondary metabolites, ligands, were retrieved from PubChem for the in-silico 
interaction assays. Prior to the molecular docking of ligand and receptor, all ligands were optimized 
by addition of hydrogen and energy minimization using Gasteiger algorithm (Gasteiger & Jochum, 
1979) in structure editing wizard of Chimera, which works on the chemoinformatic principle of 
electronegativity equilibration and the files were saved in mol2 format.    
 
Figure 1 3D image representing binding of N3 and Flaviolin at same cleft of 3CLpro (PDB ID: 6LU7) 
of COVID-19. 
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 Receptor-ligand docking analysis was performed using AutoDock Vina (Trott & Olson, 2010) and 
the program was executed as an add-on in Chimera. The ligand binding site in 3CLpro was selected 
based on the crystallized cognate ligand (N3), attached in the original pdb file and the co-ordinates 
were recorded for docking of fungal ligands. Further, the coordinates of hydrophobic cavity of 3CLpro 
active site was used in the docking of N3 (as control) and the fungal metabolites.  
In the AutoDock Vina algorithm, the following parameters were set as: (i) number of binding 
modes- 10; (ii) exhaustiveness of search- 8 and (iii) maximum energy difference- 3 kcal/mol. Out of 
all the possible poses suggested by AutoDock Vina, the pose showing maximum hydrogen bonds and 
minimum binding free energy change (kcal/mol), as represented in the ViewDock window, were 
chosen. They were further analysed in Biovia Discovery Studio (DS) visualizer for the formation of 
hydrogen bonds, in addition to other supporting hydrophobic interactions, by the functional groups of 
ligands with the amino acids of 3CLpro. The metabolite (ligand) making maximum number of H-
bonds, showing capability to form covalent interaction with 3CLpro and showed highest binding 
affinity was chosen for further study using molecular dynamics simulation. 
Figure 2 Interaction of N3 in the binding cleft of 3CLpro (PDB ID: 6LU7) of COVID-19 shown in 3D 
representation and 2D representation describing ligands interactions by formation of various H-bonds 
and hydrophobic interactions with protein. 
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 The structure analysis of SARS-CoV2 3CLpro shows that, the substrate binding site is located in 
the Cys-His catalytic dyad. Domain I extend from residues 8 to 101 and Domain II ranges from 
residues 102 to 184 comprise of antiparallel β-barrel structure. Domain residues is formed from 
residue 201 to 303 and possess five α-helices arranged into a largely antiparallel globular cluster, 
which is connected to domain II means of a long loop region extending from residue 185 to 200. For 
COVID-19, the substrate binding site is located in the cleft between Domain I and II. Binding of N3 
with 3CLpro shows that it binds in the substrate binding pocket in (Figure 1). N3 is relatively a large 
molecule where its backbone forms an antiparallel sheet with residues 164 to168 (His164, Glu166, 
Met165, Leu167, Pro168) of 3CLpro while also interacting with residues 189 to191 (Gln189, Thr190, 
Ala191) of the loop that links Domain II and III.  
 
Figure 3 Interaction of Flaviolin in the binding cleft of 3CLpro (PDB ID: 6LU7) of COVID-19 shown 
in 3D representation and 2D representation describing ligands interactions by formation of various H-
bonds and hydrophobic interactions with protein. 
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 The group of scientists who co-crystalized this protein with N3 also suggest strong covalent bond 
formed by Cys145 of 3CLpro with N3 of the 1.8 Å length, in turn, making the interaction with of this 
inhibitor bind irreversibly with the protein.  Briefly, the inhibitor N3 makes six hydrogen bonds (with 
Gly143, Phe140, His163, His164, Glu166 and Thr190), one amide pi-stacked interaction (with 
Leu141), five pi-alkyl interactions (with His41, Met49, Leu167, Pro168 and Ala191) two carbon 
hydrogen bonds (Met165 and His172) and one van der Walls interactions (with Asn142) with 3CLpro. 
For the docking of fungal metabolites with 3CLpro, the coordinates of N3 binding were used to assess 
the binding affinity of various fungal metabolites with 3CLpro. On performing the docking of all the 
metabolites one by one with 3CLpro, it was observed that, only five molecules were able to make three 
hydrogen bonds or more with 3CLpro at the binding cleft of N3.  These were Asperic acid, Aspernigrin 
A, Aurosperone B, Carbomymethyl-3-hexylmaleic acid and the best one, flaviolin. Flaviolin showed 
to make eight hydrogen bonds in total (with Leu141, Gly143, Ser144, Cys145, His163, Glu166 and 
Gln189) and made one carbon hydrogen bond (with Asn142) and the docking energy as predicted by 
AutoDock Vina was -7.3 kcal/mol for the best pose (Figure 2).  As shown previously, N3 showed 
interaction with residues 164 to168 (His164, Glu166, Met165, Leu167, Pro168) of 3CLpro along with 
interacting with residues 189 to191 (Gln189, Thr190, Ala191) of the loop that links Domain II and 
III, flaviolin also showed similar interaction with 3CLpro. All these properties make flaviolin as the 
best choice as the most suitable inhibitor for 3CLpro. When the docked best pose of flaviolin was 
made to superimpose with that of N3 on 3CLpro, it was observed that it was able to bind exactly at 
the same N3 binding cleft (Figure 1). Moreover, the docking analysis suggested that flaviolin 
interacted with almost all similar amino acids akin to N3-3CLpro binding.  
Further, to validate the results of docking, the comparative molecular dynamics (MD) simulation was 
performed in two pairs of experiments studying (i) N3-3CLpro and (ii) Flaviolin-3CLpro individually 
and their results were compared. Steepest descent energy minimization was performed for both the 
systems, and the systems were equilibrated under NVT (constant number of particles, volume and 
temperature) conditions for 1000 ps at 300 K, and the MD run was initiated. Once the NVT run was 
completed the system was proceeded with NPT (constant number of particles, pressure, and 
temperature) simulation and MD run was performed for 1000 ps. Trajectories were analysed for root-
mean-square deviation (RMSD), root-mean-square fluctuation (RMSF), radius of gyration (Rg) and 
the number of H-bonds formed between the ligand and proteins using ‘gmx rms’,’gmx rmsf’, ‘gmx 
gyrate’ and ‘gmx hbond’ of GROMACS utilities (Bekker et al., 1993; Pronk et al., 2013). Ligand–
protein stability was determined by the dynamics of hydrogen bonds between ligand and protein with 
respect to time. XMgrace tool was used to prepare the graphs (Turner, Land-Margin Research, & 
Technology, 2005).  
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Figure 4 Representation RMSDs of (a) 3CLpro backbone RMSD during interaction with N3 (black) 
and Flaviolin (red), (b) Radius of gyration of Cα atoms of 3CLpro of COVID-19 in the presence of N3 
(black) and Flaviolin (red), (c) RMSF values of 3CLpro backbone during its interaction with N3, (d) 
RMSF values of 3CLpro backbone during its interaction with Flaviolin (e) ligand N3’s RMSF values 
during simulation, and (f) ligand Flaviolin’s RMSF values during simulation; Hydrogen Bonds 
formed by (g) N3 and (h) Flaviolin with 3CLpro of COVID-19 during simulation. 
8 
 
 The RMSD values for the backbone of proteins in presence of both the ligands, 3CLpro was found 
to be more stable in presence of flaviolin as compared to N3. Though, on stabilization of the system 
after 500 ps of MD run, the RMSD values were almost equal (Figure 4a). Radius of gyration (Rg) 
was determined to understand the level of compaction in the structure of 3CLpro in the presence of N3 
and Flaviolin. The Rg is defined as the mass weighted root mean square distance of a collection of 
atoms from their common center of mass. Hence this analysis gives us the overall dimensions of the 
protein. The calculated Rg values over the simulation time scale for (i) N3-3CLpro and (ii) Flaviolin-
3CLpro are shown in Figure 4b. The Rg value of N3-3CLpro and Flaviolin-3CLpro varies between 2.192 
nm and 2.190 nm. From the Rg plot, it shows that Flaviolin-3CLpro has marginally lower Rg values, 
however the difference cannot be considered significant. This suggest the protein behave identical in 
presence of N3 and Flaviolin. 
 The RMSF with respect to the average MD simulation conformation reflects as a mean portraying 
flexibility differences among residues. The RMSF of the backbone atoms of each residue in the (i) 
N3-3CLpro and (ii) Flaviolin-3CLpro individually is calculated to reveal the flexibility of the backbone 
structure in presence of both ligands. This shows how the protein behaves in presence of different 
ligands. The high RMSF value indicates more flexibility whereas the low RMSF value indicates 
limited movements during simulation in relation to its average position. The RMSF of the protein 
backbone 3CLpro in presence of both the ligands N3 and Flaviolin were almost identical suggesting 
similar affinity of binding with the protein. If the binding is poor than the protein is freer to hive 
higher RMSF values, which is not the case here (Figure 5c, d).  While the RMSF of the ligands N3 
and Flaviolin is shown in Figure 5e and f respectively. As both the ligands are differing in size and 
shapes, comparing their RMSF doesn’t hold any importance. 
 The intermolecular hydrogen bonding between the protein and the ligand plays an essential role in 
stabilizing the protein–ligand complexes. The stability of the hydrogen bond network formed between 
(i) N3-3CLpro and (ii) Flaviolin-3CLpro were calculated throughout the simulation at 300 K for the 
ligated system and the results are depicted in Figure 5e and f.  The N3-3CLpro complex exhibited four 
hydrogen H-bonds upto 500ps and thereafter the number of hydrogen bond increased to the average 
of six suggesting the ligand getting more stable during the course of MD run. While for Flaviolin-
3CLpro, there were consistently six hydrogen bonds being formed throughout the simulation. Overall 
scenario suggests both ligands fits in to the binding cleft making appropriate hydrogen bonds.
 From the MD analysis it can be said that the protein behaves identical in presence of both the 
ligands, N3 and Flaviolin both forms similar hydrogen bonds with 3CLpro and hence the efficacy of 
Flaviolin to interact with 3CLpro can be depicted to be at par with N3.  
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Table 1 ADMET prediction of N3 an Flavolin.  
Model Name 
N3 Flaviolin 
UNIT Predicted 
Value 
Predicted 
Value 
Water solubility -4.181 -2.042 (log mol/L) 
Caco2 permeability 0.501 0.215 (log Papp in 10-6 cm/s) 
Intestinal absorption 62.398 62.173 (% Absorbed) 
Skin Permeability -2.736 -2.771 (log Kp) 
P-glycoprotein substrate Yes No (Yes/No) 
P-glycoprotein I inhibitor Yes No (Yes/No) 
P-glycoprotein II inhibitor No No (Yes/No) 
VDss (human) -0.764 0.313 (log L/kg) 
Fraction unbound (human) 0.052 0.685 Numeric (Fu) 
BBB permeability -1.725 -0.776 (log BB) 
CNS permeability -4.013 -3.294 (log PS) 
CYP2D6 substrate No No (Yes/No) 
CYP3A4 substrate Yes No (Yes/No) 
CYP1A2 inhibitor No No (Yes/No) 
CYP2C19 inhibitor No No (Yes/No) 
CYP2C9 inhibitor No No (Yes/No) 
CYP2D6 inhibitor No No (Yes/No) 
CYP3A4 inhibitor Yes No (Yes/No) 
Total Clearance 0.713 0.425 (log ml/min/kg) 
Renal OCT2 substrate No No (Yes/No) 
AMES toxicity No No (Yes/No) 
Max. tolerated dose 
(human) 
0.015 0.29 (log mg/kg/day) 
hERG I inhibitor No No (Yes/No) 
hERG II inhibitor Yes No (Yes/No) 
Oral Rat Acute Toxicity 
(LD50) 
4.138 1.544 (mol/kg) 
Oral Rat Chronic Toxicity 
(LOAEL) 
3.606 2.688 (log mg/kg_bw/day) 
Hepatotoxicity Yes No (Yes/No) 
Skin Sensitisation No No (Yes/No) 
T. Pyriformis toxicity 0.285 0.288 (log ug/L) 
Minnow toxicity 4.885 2.952 (log mM) 
  
 The pkCSM - pharmacokinetics server (Pires, Blundell, & Ascher, 2015) was used to 
predict the ADMET (absorption–distribution–metabolism–excretion–toxicity) properties of 
N3 and flaviolin. It predicted both physiochemical and pharmacological properties. SMILES 
(Simplified Molecule Input Line Entry Specification) of the compounds were retrieved from 
PubChem and uploaded to pkCSM - pharmacokinetics server (Table 1).  Of all the tests, 
Flaviolin showed better distribution based on the values of volume of Distribution (VDss). 
Flaviolin also showed fraction unbounded showing its ability to distribute in tissues of body 
more effectively. Flaviolin does not even interfere the Cytochrome (CYP) and has better renal 
clearance. Lastly the toxicity by Flaviolin on liver cells is also not predicted and hence it has 
10 
 
better drug like properties when compared to N3. With efforts been made to control the 
pandemics of SAR-CoV2 in the form of novel coronavirus, to find the lead compound against 
the target protein that can suppress its.  
 Reflecting back in the history, fungal metabolites have been a boon for the mankind, 
starting from antibiotics to flavoring agents to food preservatives. Fungi are known to produce 
large amounts of secondary metabolites and by chance that might interact with 3CLpro, with 
this rationale the fungal metabolites were looked for pursuing this research. Previously, the 
potentials of fungal metabolites as anti-viral agents are explored and the success was 
promising. The anti-viral compounds from fungal origin is vividly described by Linnakoski et 
al. (2018) where the promising anti-viral compounds portrayed were belong to the chemical 
class of Indole alkaloids, Non-ribosomal peptides, Polyketides, Terpenoids. With efforts been 
made to control the pandemic of SAR-CoV2 in the form of novel Coronavirus, to find a lead 
compound against the target protein that can suppress its. We here are proposing Flaviolin to 
interact with one of the important target proteins of SAR-CoV2, 3CLpro and block its function 
as deduced using docking and molecular dynamics. 
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